India, Oct. 20 -- Hansoh Pharmaceutical Group Co., Ltd. (HNSPF), a China-based pharmaceutical company, has entered into a strategic collaboration and licensing agreement with Roche Holding AG (RHHBY) to advance a broad portfolio of antibody-drug conjugate (ADC) programs targeting multiple cancer types.
Under the agreement, Hansoh is eligible to receive an upfront payment of $400 million, a first-anniversary payment of $110 million and potentially more than $15 billion in milestone payments tied to development, regulatory approvals and commercialization. The deal also includes tiered royalties on potential future product sales.
The collaboration covers two preclinical ADC programs developed by Hansoh and multiple programs based on targets ...